Traumatic Brain Injury (TBI) continues to be a significant public health issue worldwide, impacting millions each year and resulting in considerable morbidity and mortality. These injuries, which range from mild concussions to severe brain damage, often lead to enduring cognitive, emotional, and physical impairments. The pathogenesis of TBI is complex, involving both primary injuries, which occur at the moment of impact, and secondary injury processes that develop over hours to days following the initial trauma.
Primary injuries cause the immediate mechanical disruption of brain tissue, including neuronal and axonal damage, contusions, and intracranial hemorrhages. These initial injuries set the stage for secondary injury mechanisms, which involve a cascade of biochemical and molecular events such as excitotoxicity (excessive neurotransmitter release causing neuronal damage), oxidative stress (overproduction of reactive oxygen species), and programmed cell death. Understanding these intricate and interrelated pathways is crucial for developing effective therapeutic strategies to mitigate neuronal damage and improve clinical outcomes. Recent advances in neuroimaging, biomarker discovery, and molecular biology have significantly enhanced our understanding of TBI pathophysiology, opening new avenues for targeted interventions.
Currently, drug therapy for TBI faces considerable challenges. One primary obstacle is the incomplete understanding of TBI mechanisms, compounded by a lack of reliable and accurate biomarkers to reveal disease progression and drug efficacy. This Research Topic will highlight recent advancements in the pathophysiological understanding of TBI and explore innovative pharmacological treatments aimed at reducing the impact of brain injuries. We will focus on all progress and challenges in prevention, clinical care, and research related to TBI.
The theme of our Research Topic is "Mechanisms of Traumatic Brain Injury and its Pharmacotherapy." We welcome all types of articles providing new insights from experimental models and clinical pharmacological studies concerning the disease mechanisms and pharmacological treatment of all types of TBI, especially those focusing on targets for pharmacological intervention and novel approaches. We hope these contributions will pave the way for translational approaches that can significantly improve the quality of life for individuals affected by TBI. Article types include, but are not limited to, original research, reviews, case reports, and letters.
Traumatic Brain Injury (TBI) continues to be a significant public health issue worldwide, impacting millions each year and resulting in considerable morbidity and mortality. These injuries, which range from mild concussions to severe brain damage, often lead to enduring cognitive, emotional, and physical impairments. The pathogenesis of TBI is complex, involving both primary injuries, which occur at the moment of impact, and secondary injury processes that develop over hours to days following the initial trauma.
Primary injuries cause the immediate mechanical disruption of brain tissue, including neuronal and axonal damage, contusions, and intracranial hemorrhages. These initial injuries set the stage for secondary injury mechanisms, which involve a cascade of biochemical and molecular events such as excitotoxicity (excessive neurotransmitter release causing neuronal damage), oxidative stress (overproduction of reactive oxygen species), and programmed cell death. Understanding these intricate and interrelated pathways is crucial for developing effective therapeutic strategies to mitigate neuronal damage and improve clinical outcomes. Recent advances in neuroimaging, biomarker discovery, and molecular biology have significantly enhanced our understanding of TBI pathophysiology, opening new avenues for targeted interventions.
Currently, drug therapy for TBI faces considerable challenges. One primary obstacle is the incomplete understanding of TBI mechanisms, compounded by a lack of reliable and accurate biomarkers to reveal disease progression and drug efficacy. This Research Topic will highlight recent advancements in the pathophysiological understanding of TBI and explore innovative pharmacological treatments aimed at reducing the impact of brain injuries. We will focus on all progress and challenges in prevention, clinical care, and research related to TBI.
The theme of our Research Topic is "Mechanisms of Traumatic Brain Injury and its Pharmacotherapy." We welcome all types of articles providing new insights from experimental models and clinical pharmacological studies concerning the disease mechanisms and pharmacological treatment of all types of TBI, especially those focusing on targets for pharmacological intervention and novel approaches. We hope these contributions will pave the way for translational approaches that can significantly improve the quality of life for individuals affected by TBI. Article types include, but are not limited to, original research, reviews, case reports, and letters.